Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Use of gemtuzumab ozogamycin combined with conventional chemotherapy in patients with acute myeloid leukemia

Einstein (São Paulo), June 2011

26760814

Guilherme Fleury Perini, Fabio Pires de Souza Santos, Iracema Esteves, Claudia Mac-Donald Bley do Nascimento, Morgani Rodrigues, Reijane Alves de Assis, Ricardo Helman, Jose Mauro Kutner, Andreza Alice Feitosa Ribeiro, Nelson Hamerschlak

To analyze the outcome of patients treated with gemtuzumab ozogamycin combined with conventional therapy treated at Hospital Israelita Albert Einstein. 14 patients who had high risk features (secondary leukemia, unfavorable cytogenetics, and refractory disease) were treated with gemtuzumab ozogamycin combined with conventional therapy and their outcome was analysed by reviewing their medical records. Overall response rate was 58%, with 43% achieving complete response, with a median follow-up of 11 months, event-free survival was 3 months. Eleven patients died, 6 of them due to refractory acute myeloid leukemia. Only four patients presented with grade 3 to 4 toxicities and only one patient had sinusoidal obstruction syndrome after bone marrow transplant. gemtuzumab ozogamycin combined with chemotherapy is a feasible treatment regimen in acute myeloid leukemia patients. However, further studies are necessary to clarify which subgroup of patients may beneft from this treatment.